LUMA Vision, maker of a machine learning-powered 4D cardiac imaging and navigation platform, announced that it has secured $22 million in Series A3 funding.
The round was led by existing investors ABV Uni Fund, imec.xpand, and EQT Lifesciences, with participation from new investors Bayern Kapital, Atlantic Bridge Growth Fund, and an undisclosed strategic investor.
function
LUMA, a spin-out from Trinity College, Dublin, has developed a heart-focused 4D imaging and navigation platform called VERAFEYE. This enables real-time soft tissue imaging that facilitates intracardiac and intravascular navigation.
LUMA Vision, which has offices in Dublin and Munich, plans to use the funding to obtain US FDA clearance for VERAFEYE, lay the foundation for commercialization in the US, and further develop its platform.
“Doctors need accurate, real-time data at the point of care to effectively treat patients,” Fionn Larhart, CEO of LUMA Vision, said in a statement. “Our goal with VERAFEYE is to provide physicians with the data and image processing they need to treat as many of the conditions their patients face in one system. By developing a tunable technology platform, VERAFEYE has the potential to become the foundation of medical imaging for years to come.”
market snapshot
Other companies offering 4D technology include: GE Healthcare with the Voluson i platform, a 4D compact ultrasound system for women’s healthcare, and Canon Medical Systems (formerly Toshiba Medical Systems), a Japanese company with the AI-powered Alphenix 4D CT technology. .